Chemotherapy in the management of advanced cutaneous malignant melanoma Journal Article
| Authors: | Luke, J. J.; Schwartz, G. K. |
| Article Title: | Chemotherapy in the management of advanced cutaneous malignant melanoma |
| Abstract: | The recent past has witnessed unprecedented clinical progress in the treatment of advanced malignant melanoma through targeting of mutant BRAF in approximately 50% of patients and immune check point blockade in all patients. As has been well documented, responses to targeted therapy are of limited duration, and rates of clinical benefit to immunotherapy are modest. Given these factors, palliation of patients with chemotherapy remains an essential aspect of melanoma oncology. Many chemotherapeutics (and combinations with other agents, such as immunotherapy) have been evaluated in melanoma, although no chemotherapy regimen has been documented to provide an overall survival benefit in a prospective, randomized, well-controlled phase III study. We provide an overview of the development of the most common chemotherapy regimens for melanoma, discuss the clinical trial evidence supporting and contrasting them, and highlight appropriate clinical situations in which they might be used. We also discuss the future of chemotherapy for melanoma, noting the potential for combinations of chemotherapy with either targeted or immunotherapeutic agents. © 2013 Elsevier Inc. |
| Keywords: | cancer chemotherapy; gene mutation; overall survival; fatigue; sorafenib; bevacizumab; cisplatin; advanced cancer; cancer combination chemotherapy; drug dose reduction; drug efficacy; drug withdrawal; nonhuman; patient selection; alpha interferon; paclitaxel; cancer adjuvant therapy; temozolomide; drug megadose; carboplatin; dacarbazine; interleukin 2; ipilimumab; lomeguatrib; cancer immunotherapy; melanoma; progression free survival; anemia; bone marrow suppression; leukopenia; nausea; neuropathy; thrombocytopenia; vincristine; carmustine; lomustine; vinblastine; drug dose escalation; lymphocytopenia; chemotherapy induced emesis; gastrointestinal toxicity; glioblastoma; bleomycin; tamoxifen; colitis; clinical decision making; vinca alkaloid; platinum complex; alopecia; oblimersen; b raf kinase; cutaneous melanoma; olaparib; braf gene; fotemustine; metastatic melanoma; molecularly targeted therapy; systemic disease; veliparib; vemurafenib |
| Journal Title: | Clinics in Dermatology |
| Volume: | 31 |
| Issue: | 3 |
| ISSN: | 0738-081X |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-05-01 |
| Start Page: | 290 |
| End Page: | 297 |
| Language: | English |
| DOI: | 10.1016/j.clindermatol.2012.08.016 |
| PROVIDER: | scopus |
| PUBMED: | 23608448 |
| PMCID: | PMC3709980 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 June 2013" - "CODEN: CLDEE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work